Bionano Genomics, Inc. (BNGO) CSO lists 54,000-share stock option position

Rhea-AI Filing Summary

Bionano Genomics, Inc. reports that Chief Scientific Officer Hastie Alex Reid holds a stock option (right to buy) covering 54,000 shares of Common Stock at an exercise price of $1.12 per share, with an expiration date of August 2, 2036.

According to the vesting terms, 25% of the option shares vest and become exercisable on August 2, 2027, and the remaining shares vest in 36 equal monthly installments thereafter, subject to his Continuous Service under the company's 2018 Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hastie Alex Reid

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F1	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 54,000 shares (Direct)

Footnotes (1)

1. F1. 25% of the shares subject to the option shall vest and become exercisable on August 2, 2027, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from August 2, 2027, subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each such applicable vesting date.

Key Figures

Underlying option shares: 54000.0000 shares Exercise price: $1.1200 per share Option expiration date: 2036-08-02 +2 more

5 metrics

Underlying option shares 54000.0000 shares Stock Option (Right to Buy) for Common Stock held directly by Hastie Alex Reid

Exercise price $1.1200 per share Exercise price for the Stock Option (Right to Buy) on Common Stock

Option expiration date 2036-08-02 Expiration date of the reported stock option position

Initial vesting portion 25% of shares Portion of option shares that vest and become exercisable on August 2, 2027

Remaining vesting installments 36 monthly installments Remaining shares vest in 36 successive equal monthly installments from August 2, 2027

Key Terms

Stock Option (Right to Buy), Continuous Service, 2018 Plan, underlying security

4 terms

Stock Option (Right to Buy) financial

"Security title is listed as Stock Option (Right to Buy)"

Continuous Service financial

"subject to the Reporting Person's Continuous Service as defined in the 2018 Plan"

2018 Plan financial

"as defined in the Company's 2018 Plan through each such applicable vesting date"

underlying security financial

"underlying security title is identified as Common Stock"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/05/2026 - 04:01 PM Accepted by SEC EDGAR 08/05/2026 - 04:00 PM Learn about SEC filing dates

FAQ

What stock option holding did Bionano Genomics (BNGO) report for Hastie Alex Reid?

Bionano Genomics reported that Hastie Alex Reid holds a stock option for 54,000 shares of Common Stock at an exercise price of $1.12 per share. The option is a Stock Option (Right to Buy) and remains outstanding as a direct holding.

When do the BNGO stock options for Hastie Alex Reid begin vesting?

Vesting on this BNGO stock option begins on August 2, 2027, when 25% of the shares vest and become exercisable. The remaining shares then vest in a series of 36 equal monthly installments measured from that same August 2, 2027 date.

What is the exercise price of Hastie Alex Reid’s Bionano Genomics (BNGO) stock option?

The exercise price of Hastie Alex Reid’s stock option is $1.12 per share for the underlying Common Stock. This price applies to each of the 54,000 underlying shares covered by the Stock Option (Right to Buy) reported as a direct holding.

When does the reported Bionano Genomics (BNGO) stock option held by Hastie Alex Reid expire?

The reported stock option held by Hastie Alex Reid expires on August 2, 2036. This expiration date applies to the Stock Option (Right to Buy) covering 54,000 shares of Common Stock, assuming the option has vested and remains outstanding under its terms.

How do the remaining BNGO option shares vest after the initial 25% for Hastie Alex Reid?

After the initial 25% vests on August 2, 2027, the remaining option shares vest in 36 successive equal monthly installments. Each installment is subject to Hastie Alex Reid’s Continuous Service, as defined under Bionano Genomics’ 2018 Plan, through the applicable vesting dates.

What does Continuous Service mean for the vesting of Bionano Genomics (BNGO) options held by Hastie Alex Reid?

The vesting terms require Hastie Alex Reid’s Continuous Service as defined in Bionano Genomics’ 2018 Plan. Option shares vest only if he continues in such service through each scheduled vesting date, including the August 2, 2027 cliff and the 36 monthly installments.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hastie Alex Reid

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/03/2026

3. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	08/02/2036	Common Stock	54,000	$1.12	D

Explanation of Responses:

1. 25% of the shares subject to the option shall vest and become exercisable on August 2, 2027, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from August 2, 2027, subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each such applicable vesting date.

	/s/ Jonathan V. Dixon, Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)